Paragraf acquires Cardea Bio

Paragraf, Ltd. acquired Cardea Bio, the developer of the CRISPR-Chip graphene-based biosensor. The acquisition combines Paragraf's mass production of graphene electronics with Cardea's biosensor expertise to support CRISPR QC's gene editing analytics platform.

“We are excited to see Cardea merge into the Paragraf family.”businesswire.com

• 1 source
• businesswire.comParagraf Acquires CRISPR-Chip Developer Cardea Bio, Accelerating CRISPR QC’s Business OpportunityRoss Bundy, PresidentMay 3, 2023

Summarized from public sources; check the original articles before acting on it.